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Figure 2: Two models have been proposed to explain the mechanism by which telomeres are elongated in ALT cells ; by an unequal 
telomeric sister chromatid exchange (T-SCE).  
In the unequal T-SCE model, two sister chromatids exchange  telomeric sequences  unequally  and when the cell divide one 
daughter will receive the lengthened telomere, acquiring extended proliferative capacity whereas the other cell will receive the 
shorten telomere resulting in a cell with reduced proliferative capacity. 
In the homologous-dependent recombination DNA replication model, a chromatid from one chromosome invades telomeric sequence 
of another chromosome, using it as a template for the extension of its telomeric sequence. That leads to the extension of the second 
strand and eventually to a net gain of telomere length. Modified from: Cesare AJ et al. Nat Rev Genet (2010). 
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Introduction Methodology 
Telomeres are the capping structures of chromosomes based on a repetitive sequence 
5’-TTAGGG-3’. They protect chromosomes from external damage and procures their 
integrity. However, they present a really problematic handicap which is the inability of 
the replicative machinery to completely replicate telomeres, causing a progressive 
shortening of them with each round of cell division. When telomeres reach a limited 
length cell undergoes senescence, state in which is no more able to divide.  
In order to avoid that, immortalized cells as stem cells or germ cells possess a 
mechanism to maintain telomere length making sure to keep telomere length stable. 
The rest of somatic cells do not possess the mechanism to maintain telomere length 
that ensures their unstoppable division. However, tumour cells go against these 
statement and reactivate a telomere lengthening mechanism, giving them the ability to 
proliferate without the problem telomere shortening.  
The best known telomere maintenance mechanism (TMM) is the ribonucleoprotein 
enzyme telomerase which replenished replicative loss of telomeric DNA by using its 
integral RNA molecule as a template for reverse transcription of new telomeric DNA. 
Around the 85%-90% of tumors have an increased telomerase activity and the 
remaining 10%-15% maintain their telomeres length through an alternative 
mechanism referred to as ALT.  
The ALT is a recombination-based telomere maintain mechanism which is more 
commonly found in mesenchymal origin and neuroepithelial origin cancers although the 
reason for this is not clear. It is thought this cells could control telomerase more tightly 
leading to a more facilitated activation of ALT.  However, ALT has been also found in 
other cancer types, and intriguingly, it has also been showed to activate when tumor 
cells using telomerase are treated with telomerase inhibitors. Under this context, the 
interest for the study of ALT mechanism have increased in order 
to understand this mechanism and lately to lead to a therapeutic approach. 
 
In this review my aims have been: 
 Offering a main view of the ALT mechanism. 
 Describing the most important proteins implicated. 
 Explaining the main features of cells using ALT. 
 Putting ALT in a clinical context, discussing its prognostic value and the possibility of 
using some features for the detection and following of tumors using ALT. 
In order to carry out this review the methodology followed was based on three main statements:  
 
 
  Papers taken from scientific data base like pubmed and google. Scholar 
 
  First reading of reviews to get an approach into the topic and subsequent reading of experimental papers 
 
  The search of papers was done under this keywords: ALT, telomeres, cancer, recombination, APBs,                             
proteins, phenotype. 
 
ALT activation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1:  In same way some  tumor cells reactivate telomerase, other tumor cells using ALT undergo mutation events, either 
genetic  or genetic which affect c ells  involved in DNA damage response, transcription regulation or sumoylation.  That would lead 
to ALT activation, which is characterized for presenting the phenotypic features shown.  
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Prevalence of ALT  in  human  cancer  
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Figure 5: Overall prevalence of ALT positive tumors related to different tumor subtypes. 
The most prevalence ones are highlighted here. Sarcomas are indicated in green and 
carcinoma and central nervous system tumors are in red.  
Modified from: http://e-ducativa.catedu.es/44700165/aula/archivos/repositorio/1000/1060/html/index.html       
 
ALT assays  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this review we have seen that ALT mechanism is a recombination based TMM, even though the exact mechanism is not completely clear. Two models have been proposed, however, 
secondary mechanism could take place as well. Anyhow, these elongations are heterogeneous and telomeres are overlengthened, providing interesting features that along with other ALT 
phenotypic characteristics can be measured and could be useful to assay ALT presence. The proteins known to be required for ALT activity are present in normal cells, as they participate 
in recombination and repair functions. This has led to question whether if ALT might be or not a normal TMM, present in normal cells, in fact, this has been observed in vivo in epidermal 
stem cells in the absence of telomerase activity. Thus providing the fact that ALT mechanism might be a normal TMM, many questions emerge as, what is the reason of its existence in a 
normal cell and which mechanism uses a tumor cell to unregulated ALT normal mechanism.  
 
Clinically, it has been observed that ALT mechanism dominates in some cancer subtypes, having a special preference for mesenchymal or neuropeithelial origin. However, it was 
intriguingly found that when tumor cells using telomerase were treated with telomerase inhibitors; an ALT+ phenotype appeared, suggesting an adaptive appearance of ALT in order to 
survive. This fact, make us think about the possibility of using, in future, a double therapy approach, in which telomerase and ALT inhibitors may be administrated in order to avoid this 
selection and surviving alternative. The major comprehension of ALT would let us choose the best targeting for ALT inhibitors.  
Normal 
cells  
- Deregulation of 
sumoylation 
- P53 function impaired 
- DAXX, ATRAX,  
- H3.3 altered function 
 
ALT positive 
cells 
T-circles, ss-G, ss-C 
ECTRs 
T-SCE 
Overlengthened and 
heterogeneous 
telomeres  
APBs 
UNEQUAL T-SCE MODEL 
HOMOLOGOUS-DEPENDENT RECOMBINATION 
DNA REPLICATION MODEL 
Cell inheriting the long telomere 
and extended  proliferative 
capacity  
Cell inheriting the shorten telomere  
and reduced proliferative capacity 
 
-Astocytoma(63%) 
 
-Glioblastoma multiforme(44%) 
 
-Oligodendroglioma(20%) 
 
 
 
Lehiomiosarcomas(53%) 
Chondrosarcomas(100%)  
Results 
Table 1:  In here they are presented some phonotypical features from ALT tumors that 
could be used to assay ALT activity which would be useful in detection and following of 
ALT tumors. Table modified from: Henson JD et al. FEBS Lett. (2010).  TRF (telomeric 
terminal restriction fragments), hTR (telomerase RNA subunit), hTERT (human 
telomerase reverse transcriptase), RCA (rolling circle amplification). 
 
Conclusions 
Figure 6: Example of telomere length 
heterogeneity assay. In A  we have human 
lymphocytes ALT negative with 
homogeneous signal which reflects 
uniform telomere length. Conversely, in B 
we have chromosomes from a ALT positive 
cell line with wide variation in FISH 
signalling which reflects the large variation 
in telomere length. Source: Jegou T et al. 
Mol Bio Cell (2009).   
Figure 7: Example of C-circle assay. In 
this case they are blood samples from 
osteosacroma patients.  
CA1-CA4 had ALT+ osteosarcomas 
whereas CB1-CB3 had ALT- 
osteosacromas. They also used controls, 
N1-2, N1P, N2P.  It was observed  C-circle 
increased in blood  from ALT+ tumor 
patients. Source: Henson JD Nat 
Biotechnol (2009). 
Proposed proteins  
implicated: 
Epitheloid 
sarcoma(33%) 
Liposarcoma(24%)  
MRN 
complex 
SMC5/6 
complex 
FEN1, 
MUS81, 
FANCD2, 
FANCA  
RecQ 
helicases  
Figure 3 and 4: Some evidences had led to think that ALT 
associated PML bodies (APBs), would be the 
macromolecular platform where  ALT activity would take 
place. In here it was detected signal the same place where 
telomeric DNA was found, co-localizing in the cell. 
According to this assumption, telomeric proteins would be 
sumoylated by SUMO complex triggering the accumulation 
of SP100 and PML, assembling the APBs where telomeric 
chromatin would  be placed. At the same time, repair and 
recombination proteins like RecQ helicases would be 
recruited in order to allow telomere elongation. Once 
telomere elongation is done, APB would disassembly in a 
dynamic way.  Source: Lang M et al. J Cell Sci. (2010) and 
Chung I et al Nucleus (2012). 
Figure 4: Many proteins have been 
identified as needed for ALT telomere 
elongation. They are proteins 
involved in recombination or proteins 
from DNA damage response system. 
And can function for instance as 
telomere lengthen enhancers or APB 
assembly promoters. 
ALT models 
 
